China Pharma Holdings (CPHI) Convertible Debt (2021 - 2022)
China Pharma Holdings' (CPHI) quarterly Convertible Debt came in at $4.8 million in Q2 2022, down 4.04% quarter-over-quarter from $5.0 million in Q1 2022.
Powered by 
Analysis
China Pharma Holdings (CPHI) Convertible Debt (2021 - 2022) Analysis & Trends
China Pharma Holdings (CPHI) has reported Convertible Debt for 2 consecutive years, with $4.8 million the latest figure, recorded in Q2 2022.
- For the quarter ending Q2 2022, Convertible Debt changed N/A year-over-year to $4.8 million; the trailing twelve-month figure through Jun 2022 stood at $4.8 million (changed N/A YoY), and the FY2021 full-year result was $5.2 million, changed N/A from the prior year.
- Convertible Debt retreated to $4.8 million in Q2 2022 per CPHI's latest filing, from $5.0 million in the prior quarter.
- Across five years, Convertible Debt topped out at $5.2 million in Q4 2021 and bottomed at $4.8 million in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | China Pharma Holdings | 31.39 Mn | 31.08 Mn | 83,566.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | 4.75 Mn |
| Mar 31, 2022 | 4.95 Mn |
| Dec 31, 2021 | 5.25 Mn |